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A study was performed of consecutive patients presenting to a Dutch early arthritis clinic with a primary suggested diagnosis
of reactive arthritis due to streptococci between April 1998 and January 2003, in a well-deﬁned reference population consisting
of 600000 inhabitants. At 1 year after presentation out of 45 acute arthritis patients with initially an elevated antistreptolysin-O
and without an alternative rheumatic diagnosis only 9 patients (20%) were not diagnosed as PSRA; 16 cases (36%) were due to
NGAS, 20 cases (44%) due to GAS. The estimate of the annual incidence rate of PSRA in the Netherlands during the study was
1.26 per 100000: 0.70 GAS-related. A diagnostic set of criteria was formulated based on the original Ayoub&Ahmed criteria by
adding a serological criterium ASO/antiDNaseB ratio <1.4 and excluding a clinical criterium on chronicity/recurrency of arthritis:
likelihood ratio for a positive test 7.9 [95% conﬁdence interval (95%CI: 2.7–22.7)], for a negative test 0.06 [95%CI: 0.009–0.39].
Copyright © 2009 T. L. Th. A. Jansen. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Streptococci in man are responsible for a variety of infec-
tions, ranging from relatively mild illnesses, such as pharyn-
gitis and impetigo, to clinically severe pathologies such as
pneumonia, septicaemia, necrotizing fasciitis or myositis.
Streptococci may evoke not only bacterial/purulent but also
sterile sequelae. Classically, arthritis secondary to group
A streptococcal (GAS) pharyngitis is attributed to acute
rheumatic fever (ARF) [1], but nowadays post-streptococcal
reactive arthritis (PSRA) must be considered as well [2–5].
Dissimilarities between ARF and PSRA may exist genetically
[6], on the level of humoral hyperresponsiveness [7–9], and
on the level of clinical characteristics [10–16]. In individual
cases diagnostic criteria may be helpful for diagnosing
probably GAS-induced PSRA in particular. In 1997, Ayoub
and Ahmed have proposed a set of clinical and serological
criteria for the diagnosis of PSRA [17]: (A) acute-onset
arthritis, symmetric or asymmetric, usually nonmigratory,
(B) a protracted course or a recurrent type of arthritis,
(C) poor responsiveness to salicylates/nonsteroidals, (D)
evidence of antecedent streptococcal infection, (E) absence
of any Jones major manifestation. Though these criteria
were meant for classiﬁcation and not meant for diagnostic
use, they can be applied as a starter for diagnostic use for
clinicians:particularlycriterion(B)isunclearfromtheonset.
Clinically, rheumatologists need to homogenize groups of
PSRA patients as so far literature describes a heterogeneous
spectrum of PSRA without proven prognostic implications
[18]. This study reﬂects all new patients presenting in a
ﬁve-year period with early arthritis and at presentation
elevated streptococcal antibody titre suggestive of a recent
streptococcal infection, and not known with a previous
rheumatic condition.
2.MaterialsandMethods
2.1. Study Design. A cohort of patients was studied com-
prising consecutive patients with early and acute onset of
arthritis and at presentation a serological suggestion of a
recent infection with β-haemolytic streptococci, presenting
to our outpatient clinics of rheumatology from April 1998
until January 2003: a period of 57 months. Before inclusion,2 International Journal of Rheumatology
other causes of arthritis were excluded: septic arthri-
tis, rheumatoid arthritis, connective tissue disease, crystal
deposition disease, reactive arthritis attributable to par-
vovirus B19/salmonella/shigella/campylobacter/chlamydia/
gonococ-ci/spirochetes, and arthritis secondary to inﬂam-
matory bowel disease. An elevated antistreptolysin-O and/or
antideoxy-ribonuclease-B titre with/without tonsillopharyn-
gitis was a prerequisite for inclusion into the present
study. All patients were according to Good Clinical Practice
regularly seen on outpatient basis for followup. There was
no strict study protocol for PSRA patients, but the following
tests were obtained on routine basis in these patients: full
blood count, erythrocyte sedimentation rate, serum creati-
nine, alkaline phosphatase, gamma-glutamyltranspeptidase,
aspartate amino or alanine aminotranspeptidase, uric acid,
IgM rheumatoid factor (IgM RF), antinuclear antibodies
(ANA), C reactive protein, and urine microscopy. An
electrocardiogram was obtained of all patients. An echocar-
diogram was obtained in cases with a cardiac murmur or
with a conduction block on the electrocardiogram. Clinical
evaluation was performed by a rheumatologist, that is, the
number of joints involved was counted according the 36
swollen joint index (SJI).
During follow-up visits (t = 0, 6 weeks, 12 weeks, and
every 3 month afterwards), the diagnosis was reevaluated by
patient’s own rheumatologist, and when after one year no
alternative explanation for the arthritis had been presented,
the diagnosis of PSRA became deﬁnite. This procedure was
checked by an experienced clinician before entrance into this
study.
2.2. Serological Measurements. In all patients antistreptolys-
in-O (ASO) and antideoxyribonuclease-B (antiDNaseB)
titres were measured simultaneously and sequentially, at
least at three time points: at presentation, at 4–10 weeks
after pharyngitis, and once afterwards. When a sore throat
was not recollected, the titres of ASO and antiDNaseB
were measured every 4 weeks during a period of 3
months. The suggestion of a recent streptococcal infection
was accepted when an increased titre of ASO and/or
antiDNaseB and subsequently decrease/normalization of
titres were found: (1) ASO >200U/L in adults, ASO
>300U/L in adolescents; antiDNaseB >200U/L irrespective
of age; (2) one or both titres must primarily show a
signiﬁcant rise and subsequent decrease: critical diﬀerence
between consecutive ASO values 26% and between con-
secutive antiDNaseB values 14% [5]. Titres were deter-
mined by nephelometry kit from Behring (Marburg, Ger-
many).
PSRAwasdiagnosedbythepatient’sownrheumatologist
when after at least one year no alternative diagnosis could
be made. Deﬁnite PSRA patients were subdivided into two
separategroups,basedontheASO/antiDNaseBratiotakenat
4–10 weeks after pharyngitis/tonsillitis: ratio <1.40 a plea for
GAS-induced reactive arthritis, whereas ratio >1.5, a plea for
NGAS-induced PSRA [5]. Patients diagnosed by their own
rheumatologistortheexperiencedclinician asnon-PSRAare
grouped together into a third separate group.
2.3. Analysis of Criteria. Ayoub and Ahmed have proposed
criteria for the classiﬁcation of PSRA which may be quite
applicable for clinical use [17]: a triad regarding charac-
teristics of arthritis, one regarding evidence of antecedent
streptococcal infection, and a duplet regarding the exclusion
of acute rheumatic fever: (A) acute onset of, symmetric or
asymmetric, nonmigratory arthritis, (B) protracted course
of arthritis or recurrent arthritis, (C) poor response of
arthritistosalicylates/nonsteroidals,(D)serologicalevidence
of antecedent streptococcal infection, (E) not fulﬁlling any
modiﬁed Jones major criterion. The combination of this
quintet of criteria is tested in our study groups. Criterion
(B) is however diﬃcult to score prospectively in a diagnostic
phase from the onset in an individual patient.
A previous study from the region of Arnhem, in the
central region of the Netherlands, revealed that the higher
ASO/antiDNaseB ratios plea for PSRA types not due to
GAS, that is, ratios >1.5 plea for nongroup A streptococcal
(NGAS) infection which may be helpful particularly in
cases with a negative throat culture; ratios <1.4 plea for
GAS-induced reactive arthritis [5]. Therefore a serological
criterion which is clear from the beginning at the diagnostic
phase, is formulated for presumably GAS-induced PSRA: (F)
ASO/antiDNBratioat4–10weeks<1.4.Afurtherserological
criterion is formulated as (G) antiDNaseB >400U/L which is
twice above the upper limit of normal range (normal range:
<200U/L in adults)
The presented patient population is ﬁtted into ﬁve sets of
several combinations of criteria: starting with the ﬁve ((A),
(B), (C), (D), plus (E)) criteria adapted from Ayoub and
Ahmed, versus modiﬁcation 1, that is, a sextet consisting of
the aforementioned quintet plus (F), versus modiﬁcation 2,
that is, a sextet consisting of criteria by Ayoub and Ahmed
plus (G) and modiﬁcations 3 and 4 consisting of the sextets
minus(B):(A),(C),(D),(E),plus(F),and(A),(C),(D),(E),
plus (G), respectively.
Using the aforementioned tests, the following test char-
acteristics are calculated: sensitivity (Se), speciﬁcity (Sp),
positive predictive value (PPV), likelihood ratio of a positive
test (LR+) measured as the ratio between probability on
a positive test result in GAS-induced PSRA patients versus
nonindex patients ideally reaching to inﬁnite, and likelihood
ratio of a negative test (LR−) which is measured as the ratio
between probability on a negative test result in GAS-induced
PSRA versus nonindex patients ideally reaching to nil: using
a2× 2 table with GAS-induced PSRA diagnosed by a
rheumatologistatclassiﬁcationtime1yearafterpresentation
as the golden standard, and using several combinations of
criteria as index test, and in which a = true test positive,
b = false test positive, c = false test negative, and d = true
test negative: (legend: V[x] = square root of x; EXP[x] =
2.7182818284x)
(1) Se = a/(a + c) with 95% conﬁdence interval: Se +/−
(95%CI) 1.96∗V[ac/(a + c)3];
(2) Sp = d/(b + d) with 95%CI: Sp +/− 1.96∗V[bd/(b +
d)3];
(3) PPV = a/(a + b) with 95%CI: PPV +/− 1.96∗V[ab/(a
+ b)3];International Journal of Rheumatology 3
(4) NPV = d/(c + d) with 95%CI: NPV +/− 1.96∗V[cd/(c
+ d)3];
(5) LR+ = Se/(1 − Sp) with 95%CI: EXP[LN(LR+) +/−
1.96∗V[1/a − 1/(a + c)+1 / b –1 / ( b + d)]];
(6) LR− = (1 − Se)/Sp with 95%CI: EXP[LN(LR−)+ / −
1.96∗V[1/c − 1/(a + c)+1 / d − 1/(b + d)]].
2.4. Statistics. Intergroup comparison between probable
GAS and NGAS patients was done by Mann-Whitney’s two-
sample test. Nonparametric Spearman’s rho correlations are
calculated between ESR, CRP, ASO/ADB ratio, number of
arthritic joints, and number of weeks arthritis persists. P-
values <.05 are considered statistically signiﬁcant.
3. Results
During a period of nearly ﬁve years 45 patients with a sterile
acute arthritis with at presentation a positive streptococcal
serology presented to our outpatient department. All cases
were sporadic, and clustering of cases was not seen. In
36 patients a signiﬁcant change in streptococcal serology
was observed, and in 16 a probability of PSRA due to
group A streptococci could not be conﬁrmed as they had
group C or G streptococci in throat culture (n = 2) and
a compatible high serological ratio suggestive of nongroup
A streptococci (NGAS), that is, ASO/antiDNaseB >1.5.
Suspicion rose in a group of 20 patients during followup
that indeed group A streptococci (GAS) were the causative
organisms. This indicates an estimated annual incidence
rate for PSRA of 36 in our Dutch population, that is,
1.26/100000:GAS-relatedPSRA(n =20)indicatesanannual
incidence rate of 0.70/100000, with NGAS-related PSRA (n
= 16) 0.56/100000.
A group consisting of 9 patients presented with arthritis
plus elevated ASO but did not have a signiﬁcant increase
nor decrease in streptococcal antibody titres; and during
followup an alternative diagnosis had to be be made.
Therefore these patients are categorized into a third group
of non-PSRA. During followup they were diagnosed as
coincidental streptococcal carriers in rheumatoid arthritis
(n = 3), psoriatic arthritis (n = 3), reactive arthritis due to
Chlamydia (n = 1), L¨ ofgren syndrome (n = 1), and Lyme
arthritis (n = 1).
In GAS-induced PSRA, 4 out of 20 patients had positive
antinuclear antibodies, without any speciﬁcity. By deﬁnition
all PSRA patients have an increased ASO titre at 4–10
weeksafterasorethroat/pharyngitis,sinceseronegativecases
were excluded. In the 20 presumed GAS-induced PSRA
we obtained 7 positive throat cultures (35%): all indeed
consisted GAS; whereas in the 16 presumed NGAS cases 2
positive throat cultures (12%) were found: once group C and
once group G streptococci. The number of arthritic joints
according to the 36 swollen joint count (SJC36) is higher
in the presumed GAS- than in the presumed NGAS-induced
cases: means (SD) 5.2 (1.3) versus 1.9 (0.4). In GAS-related
PSRA the following systemic involvement was encountered:
pericarditis (1 out of 20 patients), and pneumonitis (1 out
of 20 patients), whereas in NGAS-related PSRA similar
extraarticular manifestations were not seen.
GAS-related PSRA patients all presented with a nonmi-
gratory type of arthritis; 45% had arthritis which persisted
for more than 3 months (by our deﬁnition protracted
course), and in 10% arthritis recurred. Arthritis with char-
acteristics protracted or recurrent occurred in 50%. Good
response to salicilates/nonsteroidals was seen in 1 out of
20 patients. All patients had proof of recent streptococcal
infection in serology, either in ASO and/or in antiDNaseB.
None of the patients presented with a major Jones’ criterion
other than arthritis, nor fulﬁlled Jones’ criteria on ARF.
By deﬁnition all GAS-related cases presented with a low
ASO/antiDNaseB ratio. Altogether 95% of GAS-induced
P S R Ap a t i e n t sf u l ﬁ l l e dt h ec r i t e r i aA+C+D+E+F ,b y
including criterion B this percentage dropped to 50%. When
criterion B is excluded, 75% of NGAS-induced patients meet
criteria set A + C + D+ E. In the 9 non-PSRA cases criteria
s e tA+C+D+E+Fi sm e ti n3 3 %s t i l l .
In 45 patients with acute arthritis consisting of GAS-
induced PSRA in 20, NGAS-induced PSRA in 16, and other
cases in 9, the following test characteristics for ﬁnding GAS-
induced PSRA are calculated: sensitivity (Se), speciﬁcity
(Sp), predictive value of a positive test result, that is,
positive predictive value(PPV),predictive valueofanegative
test result, that is, negative predictive value (NPV) with
95% conﬁdence intervals (95%CI). Also likelihood ratio
of positive test (LR+) and likelihood ratio of negative test
(LR−) are calculated. Prevalence of index cases, that is,
GAS-induced PSRA in this population is 44%. Only 50%
o fp a t i e n t sm e e tA+B+C+D+E ,w h i c hr e p r e s e n t s
Se, 76% Sp, with predictive values: 62.5% PPV and 65.5%
NPV, and likelihood ratio for a positive test 2.1 LR+. By
addingadditionalcriterionFspeciﬁcityincreasesto88%and
LR+ increases to 4.2. By eliminating criterion B a signiﬁcant
improvement is obtained of sensitivity and likelihood ratios:
LR+ 7.9 and LR− 0.06. The additional serological criteria (F)
or (G) give similar results regarding their additive diagnostic
value. For further data see Table 2.
3.1. Correlations. Spearman’s rho in the 36 PSRA patients
between period arthritis persists, mean (SD) 17 (35) weeks
and swollen joint count (SJC) 3.5 (4.5) joints, is 0.55 (P <
.001). In the 20 GAS-induced cases Spearman’s correlation
between period of persisting arthritis and SJC is 0.66 (P <
.005), versus 0.26 (P > .05) in NGAS-induced cases. Other
correlations are insigniﬁcant between the period arthritis
persists on the one hand and erythrocyte sedimentation
rate(ESR)/C-reactive protein(CRP) on the other.
4. Discussion
Lanceﬁeld group A streptococci (GAS) [2–5], but also
nongroup A streptococci, group C and group G [19], are
supposed to be capable to evoke reactive arthritis, though
proof is lacking in literature [18]. Post-streptococcal reactive
arthritis (PSRA) due to GAS may well be considered part of
the spectrum or possibly a forme fruste of acute rheumatic4 International Journal of Rheumatology
Table 1: Overview of 45 patients with acute arthritis subdivided into post-streptococcal reactive arthritis (PSRA) probably due to group
A streptococci (GAS) in 20, probably due to nongroup A streptococci (NGAS) in 16, and 9 non-PSRA patients. Clinical data are taken at
presentation; maximum serological data are tabulated. Legend: IgM-RF = rheumatoid factor (IgM type), ANA = antinuclear antibodies.
PSRA Presumed GAS Presumed NGAS Non-PSRA
Number of females/males 11/9 7/9 6/3
Mean age (SD) in year [range] 33 (11) [17–54] 37 (17) [12–55] 40 (16) [14–70]
Positivity for
HLA-B27 1 (5%) 0 (0%) 0 (0%)
IgM-RF 1 (5%) 0 (0%) 5 (55%)
ANA 5 (25%) 0 (0%) 2 (22%)
Antistreptolysin-O (ASO)
>200 20 (100%) 16 (100%) 6 (67%)
mean value (SEM) 1390 (235) 1055 (130) 1088 (360)
Antideoxyribonuclease-B (ADB)
>200 20 (100%) 2 (12.5%) 6 (67%)
mean value (SEM) 2730 (450) 295 (67) 340 (90)
ASO/ADB ratio
<1.4 20 (100%) 0 (0%) 3 (33%)
mean value (SEM) 0.62 (0.06) 6.2 (1.2) 9.4 (5.0)
Positive throat culture 7x GAS 2x NGAS 1x NGAS
Arthritic joints; mean number (SEM) 5.2 (1.3)∗ 1.9 (0.4) 3.4 (1.2)
monoarthritis 8 (40%) 10 (63%) 3 (33%)
oligoarthritis 7 (35%) 5 (32%) 3 (33%)
polyarthritis 5 (25%) 1 (6%) 3 (33%)
Mean duration in weeks (SD) 25 (10)∗ 5 (2.5) —
exceeding 2 months 10 (50%) 5 (31%) —
exceeding 6 months 5 (25%) 0 (0%) —
Pericarditis 1 (5%) 0 (0%) 0 (0%)
Pneumonitis 1 (5%) 0 (0%) 0 (0%)
Erythema nodosum/multiforme 1 (5%) 0 (0%) 1 (11%)
Cholestatic hepatitis 2 (10%) 0 (0%) 0 (0%)
Tenosynovitis 4 (20%) 0 (0%) 3 (33%)
∗P-value <.05 for comparison presumed GAS-induced and presumed NGAS-induced PSRA patients. GAS no. is presumed as the causative organism if the
ASO/antiDNaseB ratio is <1.4; NGAS is presumed if ASO/antiDNaseB ratio >1.5.
fever (ARF) which currently seems to have vanished from
welfaring communities. The clinical signiﬁcance of a more
benign PSRA secondary to NGAS remains unclear: it is
not known whether carditis and/or chorea risks in NGAS-
induced PSRA are similar to the risks in patients who
developed full-blown rheumatic fever. It is a challenge for
clinicians to separate these entities in a prospective manner.
Previously ARF and PSRA have been diﬀerentiated and
correctly classiﬁed by paediaticians applying simple clinical
and laboratory variables [20]. In this paper similar variables
are used to deﬁne clusters of criteria to diﬀerentiate subtypes
of PSRA, which enables homogeneity of studied cohorts in
future. Of course some circularity in reasoning cannot be
ruled out completely as most patients referred have already
been diagnosed using serological criteria which are generally
applied in the Netherlands due to previous publications
[4, 5, 10].
A resurgence over the last decades of other post-
streptococcal syndromes has been related to the spread of
diﬀerent possibly more virulent clones of streptococci,
higher number of patients with conditions interfering with
immunity, and alterations in patterns of child care [21].
In our region of the Netherlands we ﬁnd a low estimated
annualincidenceforPSRA,only0.70per100000inhabitants
for GAS-induced PSRA. Despite the resurgence of post-
streptococcal syndromes as claimed, these low incidence
rates on GAS-induced PSRA stress the importance of
multicentre cooperation in order to increase insight into risk
proﬁles for developing severe sequelae such as carditis, and
may increase our insight into long term prognosis.
Next to pyogenic sequelae, GAS infections are known
for their molecular mimicry resulting in non-pyogenic,
sterile but potentially devastating sequelae such as in acute
rheumatic fever (ARF). Patients may also develop a more
benign manifestation of post-streptococcal reactive arthritis
(PSRA), particularly when caused by nongroup A strep-
tococci (NGAS) a predictor for benign courses [19]. In
children probably more than in adults, GAS-induced PSRAInternational Journal of Rheumatology 5
Table 2: Test characteristics of three sets applied as diagnostic criteria in 45 patients consisting of 36 patients with deﬁnite post-streptococcal
reactive arthritis (PSRA) due to group A streptococci (GAS: n = 20) and due to nongroup A streptococci (NGAS: n = 16), and 9 non-PSRA
patients: calculations represent values of a screening test aiming to ﬁnd GAS-related PSRA only. Legend: Sensitivity (Se); Speciﬁcity (Sp);
Positive Predictive Value (PPV); Negative Predictive Value (NPV); Likelihood ratio (LR+) in an ideal test is optimal when ad inﬁnitum, as it
gives a ratio between probability on a positive test result in GAS-induced PSRA patients versus nonindex patients; Likelihood ratio negative
test (LR−) in an ideal test is optimal when it reaches nil, as it gives a ratio between probability on a negative test result in GAS-induced PSRA
versus nonindex patients. In the second line 95% conﬁdence intervals (95%CI) are given. For criteria (A), (B), (C), and so forth see also text
in Materials and Methods section.
Set
Original quintet Sextet 1 Sextet 2 Novel quintet 1 Novel quintet 2
Ayoub and Ahmed Modiﬁcation 1 Modiﬁcation 2 Modiﬁcation 3 Modiﬁcation 4
A, B,C ,D ,E A ,B,C ,D ,E ,F A, B,C ,D ,E ,G A, C, D, E, F A, C, D, F, G
Se 50% 50% 50% 95% 95%
95%CI 28–72% 28–72% 28–72% 85–100% 85–100%
Sp 76% 88% 92% 88% 80%
95%CI 59–93% 75–100% 81–100% 75–100% 64–96%
PPV 63% 77% 83% 86% 79%
95%CI 3 9–86% 54–100% 62–100% 72–100% 63–95%
NPV 66% 69% 70% 96% 95%
95%CI 48–83% 53–85% 54–85% 87–100% 86–100%
LR+ 2.1 4.2 6.3 7.9 4.8
95%CI 0.9–4.7 1.3–13.2 1.5–25.3 2.7–23.0 2.9–7.7
LR- 0.66 0.57 0.54 0.06 0.06
95%CI 0.40–1.08 0.36–0.90 0.35–0.86 0.008–0.39 0.009–0.42
should be considered a potential predecessor of rheumatic
heart disease, which is reﬂected in penicillin prophylaxis
regimens [22]. Currently, clinicians should be capable to
separate GAS-induced PSRA from NGAS-induced PSRA,
and this may be relevant as presently more speciﬁc risk
factors for developing a subsequent carditis are lacking. A
recent analysis of PSRA cases from literature revealed a
signiﬁcantclinicalheterogeneityofthetermPSRA[18].Prior
toanevidence-basedadviceoftherapyclarityisneededofthe
clinical entity of the PSRA diagnosis.
Only a weak genetic diﬀerence between patients with
ARF and PSRA has been demonstrated: ARF being possi-
bly associated with HLA DRB1∗16, and PSRA with HLA
DRB1∗01[6].ThiscouldnotbeconﬁrmedbySimoninietal.
[23]. It is therefore doubtful whether genetics are responsible
for an individual’s genetic susceptibility for developing the
typeofpost-streptococcalsyndrome.Humoralhyperrespon-
sivenessthenmightbehypothesizedtoexplainthespeciﬁcity
of response following streptococcal infection. A high fre-
quency of in vitro elevated D8/17 binding to B lymphocytes
hasbeenfoundasasusceptibilitymarkerfordevelopingARF
more than PSRA [7, 8, 24]. Another explanation could be in
an individual’s defense, for example, dependent on Toll-like
receptors. Next to host factors, microbacterial factors may be
important: in GAS-induced PSRA so far, the M-serotypes 9,
11, and 28 have been found, and these are M-serotypes not
known from acute rheumatic fever [25].
Clear diagnostic criteria for GAS-induced PSRA may
be helpful for clinicians. There is a need for criteria
considering the clinical heterogeneity in the PSRA diagnosis
in current literature [18]. More homogeneity may result
form an additional serological criterion of high ASO titres
with lower ASO/antiDNaseB ratios, to exclude nongroup A
streptococci. Already in 1997 Ayoub and Ahmed proposed
a set of criteria for PSRA [17]. However, some of these
cannotbeappliedatthepatient’spresentation,whichthwarts
diagnostic applicability. In the present study, a retrospective
evaluation of the potential clinical applicability of these
criteria was modiﬁed from Ayoub and Ahmed based on
Dutch experience. Half of the presented GAS-induced PSRA
patients, however, do not fulﬁl the previously proposed
criteria by Ayoub and Ahmed on PSRA. Particularly the
criterion of a protracted course of arthritis is met in only
half of presumably GAS-induced PSRA patients. It is unclear
yet whether this GAS-related PSRA patient group without
protracted arthritis bears a higher risk than the other PSRA
subgroups to develop, for example, carditis. On the other
hand, one cannot apply this feature for diagnosing purposes
at presentation as clearly a certain delay in time is needed to
meet this criterion. Interestingly, a protracted course was not
present in any of our NGAS-induced patients, diagnosed by
serological data.
Epidemiologically, in adulthood PSRA due to GAS is
estimated to occur in 0.7 per 100000 inhabitants. There may
be some underdiagnosis as clearly not all suspected patients
willhavebeenreferredtoourdepartment.Inchildhoodthese
epidemiologic data may be quite diﬀerent, probably higher.
Epidemiological reasoning to prove that PSRA really exists
cannot be done by using the presented data. Such proof
needs to be derived from immunology. Immunologically,
the classic paradigm for molecular mimicry in GAS-induced
PSRA is similar as in acute rheumatic fever after infection6 International Journal of Rheumatology
with GAS, underscoring the existence of PSRA. However,
the presence of antibodies to an antigen in the membrane
of the organism, the type 5 streptococcal M protein cross-
reactingwithtissue,hasnotbeenconvincinglydemonstrated
in PSRA. The assumed causal role of streptococcal infection
therefore remains to be demonstrated pathogenetically.
Ayoub and Ahmed have originally proposed criteria that
are applicable only in full-blown clinical situations, not
speciﬁcally for diagnostic purposes from the onset; as these
appeartoexcludehalfofourpresumablyGAS-inducedPSRA
patients [17]. An additional serological criterion, that is,
either the elevated antideoxyribonuclease-B or the lower
antistreptolysin-O/antideoxyribonuclease-B ratio (<1.4), as
described previously [5], may be applied elegantly and leads
to an improved criteria set in our presented population. Also
the criterion on a protracted course, resulting in excluding
all NGAS-induced cases, may become abundant. In order
to homogenize the PSRA patient group one might study:
(A) acute onset and nonmigratory type of arthritis, (C)
poor responsiveness of arthritis to salicylates/nonsteroidals,
(D) evidence of antecedent streptococcal infection, (E) not
fulﬁlling modiﬁed Jones criteria, plus (F) antistreptolysin-
O/antiDNaseB ratio <1.4, or (G) antiDNase-B >400U/L.
Prospective studies in other GAS-induced PSRA patient
groups are needed for validation and proving their prog-
nostic value. For purposes of homogeneity in studies the
aforementioned criteria may have some merits. For practical
purposes in an individual during the diagnostic phase a
serological criterion plus (A) and (C) seem to be quite
applicable.
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